<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501120</url>
  </required_header>
  <id_info>
    <org_study_id>APG2575AC101</org_study_id>
    <nct_id>NCT04501120</nct_id>
  </id_info>
  <brief_title>Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory AML</brief_title>
  <official_title>A Phase Ib Study of the Safety, Pharmacokinetic of APG-2575 Single Agent and in Combination With Homoharringtonine or Azacitidine in Patients With Relapsed/Refractory AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascentage Pharma Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Suzhou Yasheng Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ascentage Pharma Group Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, pharmacokinetic of APG-2575 single agent&#xD;
      and in combination with HHT/AZA in patients with relapsed/refractory AML.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center Phase Ib study of safety, PK of APG-2575 as a single&#xD;
      agent or in combination with HHT or AZA in relapsed/refractory AML patients.&#xD;
&#xD;
      This study consists of three stages: The first stage is the APG-2575 single agent escalation&#xD;
      study. The second stage is the APG-2575 combined with HHT/AZA escalation study. The third&#xD;
      stage is the MTD/RP2D expansion cohort study of the combination regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>28 days</time_frame>
    <description>DLT will be graded according to NCI CTCAE Version 5.0. DLT will be defined as clinically significant drug-related adverse events during the cycle one.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose(RP2D)</measure>
    <time_frame>28 days</time_frame>
    <description>MTD/RP2D will be determined based on DLTs observed during cycle one.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>28 days</time_frame>
    <description>Cmax of APG-2575 will be assessed in the patients in single agent or combo study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>28 days</time_frame>
    <description>AUC of APG-2575 will be assessed in the patients in single agent or combo study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 6 cycles (each cycle is 28 days).</time_frame>
    <description>ORR is defined by CR+ CRi + PR(according to IWG AML(2003)).Response will be evaluated on cycle 1 and every even cycles till completing 6 cycles treatment or end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>From date of treatment start until the date of progression or the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>From date of response until the date of progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>From date of treatment start until the date of death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Relapsed/Refractory Acute Myeloid Leukaemia</condition>
  <arm_group>
    <arm_group_label>APG2575 single agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg, to determine the MTD/RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APG2575+ reduced-dose HHT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APG-2575 MTD/RP2D-1 and MTD/RP2D combines with reduced-dose HHT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APG2575+ standard-dose HHT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APG-2575 MTD/RP2D-1 and MTD/RP2D combines with standard-dose HHT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APG2575+ AZA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APG-2575</intervention_name>
    <description>APG-2575 orally once daily, every 28 days as a cycle.</description>
    <arm_group_label>APG2575 single agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reduced-dose HHT</intervention_name>
    <description>1mg IV QD on Days 1-14 (28-day cycle).</description>
    <arm_group_label>APG2575+ reduced-dose HHT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard-dose HHT</intervention_name>
    <description>2mg/m^2 IV QD on Days 1-7 (28-day cycle).</description>
    <arm_group_label>APG2575+ standard-dose HHT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>75 mg/m^2 SC QD on Days 1- 7 (28-day cycle).</description>
    <arm_group_label>APG2575+ AZA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects who meet each of the following inclusion criteria are eligible to participate in&#xD;
        this study:&#xD;
&#xD;
          1. Age ≥18 years old.&#xD;
&#xD;
          2. In accordance with the World Health Organization (WHO) 2016 diagnostic criteria for&#xD;
             primary AML, patients diagnosed as R/R AML (blasts in bone marrow &gt;5%) after&#xD;
             treatment, except for acute promyelocytic (APL) and t(9;22) AML.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -2.&#xD;
&#xD;
          4. Subjects can accept oral administration of APG-2575.&#xD;
&#xD;
          5. Life expectancy ≥ 3 months.&#xD;
&#xD;
          6. Adequate renal and liver function.&#xD;
&#xD;
          7. Males, female patients of childbearing potential (postmenopausal women who must have&#xD;
             been menopausal for at least 12 months to be considered infertile) and their partners&#xD;
             voluntarily take contraception which the investigator considers effective during&#xD;
             treatment and at least three months after the last dose of study drug.&#xD;
&#xD;
          8. Ability to understand and willingness to sign a written informed consent form (the&#xD;
             consent form must be signed by the patient prior to any study-specific procedures).&#xD;
&#xD;
          9. Willingness and ability to comply with study procedures and follow-up examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any of the following exclusion criteria are not to be enrolled in this&#xD;
        study:&#xD;
&#xD;
          1. Patients diagnosed as acute promyelocytic leukemia (FAB classification AML-M3 or WHO&#xD;
             diagnosis classification APL with PML-RARα) or BCR-ABL positive AML patients.&#xD;
&#xD;
          2. White blood cell (WBC) ≥100×109/L when screening.&#xD;
&#xD;
          3. The persistent toxicities caused by previous chemotherapy or radiotherapy has not been&#xD;
             restored to lower than grade 2 by CTCAE 5.0 (except for alopecia).&#xD;
&#xD;
          4. Known leukemia infiltration of the central nervous system.&#xD;
&#xD;
          5. Symptomatic active fungal, bacterial and/or viral infections, including but not&#xD;
             limited to active human immunodeficiency virus (HIV), viral hepatitis B or C (type B&#xD;
             or C).&#xD;
&#xD;
          6. Prior history of allogeneic hematopoietic stem cell transplantation or adoptive cell&#xD;
             immunotherapy or autologous hematopoietic stem cell transplantation within 12 months.&#xD;
&#xD;
          7. Requirement of therapeutic doses of anticoagulants and antiplatelet drugs, but allow&#xD;
             the use of low doses of anticoagulants to maintain the opening of the central venous&#xD;
             catheter.&#xD;
&#xD;
          8. Within 14 days before the first dose of study drug, received radiotherapy, surgery,&#xD;
             immunotherapy, hormone therapy, targeted therapy, biological therapy or Chinese herbal&#xD;
             therapy or any investigational treatment.&#xD;
&#xD;
          9. Within 14 days before the first dose of study drug, received hematopoietic cytokines&#xD;
             (granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony&#xD;
             stimulating factor (GM-CSF), or erythropoietin) .&#xD;
&#xD;
         10. Failure to recover adequately, at the discretion of the investigator, from prior&#xD;
             surgical procedures, including patients who have had major surgery within 28 days&#xD;
             before the first dose of study drug, and patients who have had minor surgery&#xD;
             (excluding pathological biopsy) within 14 days before the beginning of study.&#xD;
&#xD;
         11. At the discretion of the investigator, gastrointestinal diseases that affect the&#xD;
             absorption of APG-2575.&#xD;
&#xD;
         12. Unstable angina, myocardial infarction, coronary artery reconstruction, or severe&#xD;
             gastrointestinal bleeding occurred during the 180 days before the start of study.&#xD;
&#xD;
         13. Uncontrolled complications include but not limited to: uncontrollable severe&#xD;
             infections, symptomatic congestive heart failure, unstable angina, arrhythmia, or&#xD;
             mental illness/social environment that may affect compliance.&#xD;
&#xD;
         14. The last treatment before signing the informed consent was a Bcl-2 inhibitor (subjects&#xD;
             who had been treated with a Bcl-2 inhibitor but had not developed drug resistance&#xD;
             could be enrolled in this study).&#xD;
&#xD;
         15. Any other condition or circumstance, at the discretion of the investigator, that&#xD;
             patients would be unsuitable for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yifan Zhai, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Suzhou Yasheng Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Jin, M.D.</last_name>
    <phone>+86 571-87236896</phone>
    <email>jiej0503@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Jiang, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Liang, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Tumor Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xudong Wei, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital medical college Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiubo Li, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Hunan university</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuling Zhou, Professor</last_name>
    </contact>
    <contact_backup>
      <last_name>Jianying Zhou, Professor</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yajing Xu, Master</last_name>
    </contact>
    <contact_backup>
      <last_name>Qun He, Master</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Jin, M.D.</last_name>
      <phone>+86 571-87236896</phone>
      <email>jiej0503@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>APG-2575</keyword>
  <keyword>Acute Myeloid Leukaemia (AML)</keyword>
  <keyword>Bcl-2 Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

